Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Thrombocytopenia 14Leukemia, Myeloid, Acute 11Leukemia 7Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 4Leukemia, Lymphocytic, Chronic, B-Cell 3Jacobs syndrome 3Sarcoma 2Purpura, Thrombocytopenic, Idiopathic 2Multiple Myeloma 2Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Hematologic Neoplasms 2Congenital Abnormalities 2Solid Tumor, Childhood 1Recurrence 1Primary Myelofibrosis 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Connective and Soft Tissue 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

eltrombopag 1adagrasib 1Peptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Healthy Adults × eltrombopag × Clear all
NCT05924152 2024-03-13

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Mirati Therapeutics Inc.

Phase 1 Completed
16 enrolled

Healthy Adults

Data powered by HemOnc (CC BY 4.0) Colophon âš¡